Repatha lowers risk of first major heart events by 25% in Amgen’s Phase 3 VESALIUS-CV trial
Amgen announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events (MACE) in high-risk adults without a prior heart attack or stroke




















